Shares of Supriya Lifescience surged 16.50% to Rs 940.50 during Friday’s trading session after the company reported a strong set of Q4FY26 results. The rally was supported by robust revenue growth, improving operational performance, and sustained demand from export markets.
The pharmaceutical company posted an impressive 47% year-on-year rise in Profit After Tax (PAT) for Q4FY26 at Rs 74.23 crore, compared to Rs 50.37 crore in the corresponding quarter of the previous year. Revenue from operations jumped 50.2% YoY to Rs 276.53 crore against Rs 184.11 crore in Q4FY25, reflecting strong traction across key therapeutic segments and regulated markets.EBITDA for the quarter stood at Rs 97.62 crore, rising from Rs 67.58 crore in the year-ago period.
For the full financial year FY26, Supriya Lifescience reported healthy growth across all major financial parameters. Revenue from operations increased 18.9% YoY to Rs 827.87 crore from Rs 696.48 crore in FY25. EBITDA rose 12.8% to Rs 294.05 crore compared to Rs 260.79 crore last year, while PAT climbed 11.3% YoY to Rs 209.12 crore against Rs 187.96 crore in FY25.
The anaesthetic segment continued to remain the company’s key growth driver during FY26, while newly launched products in the cardiovascular and ADHD segments also witnessed encouraging traction. Export contribution remained strong, supported by diversified customer relationships and increasing penetration into regulated global markets.
During the year, the company commercialised its Liquid Anaesthetic product and continued to strengthen its manufacturing capabilities. Capacity utilisation improved to 74% from 70% in FY25, aided by the ramp-up of Module E at the Lote facility and operational efficiencies.
Supriya Lifescience also expanded its long-term manufacturing roadmap through strategic land acquisitions near existing facilities and at Isambe, Patalganga. Additionally, its Ambernath formulation facility commissioned five finished dosage manufacturing lines and continued progress on validation and dossier submissions across regulated markets.
Commenting on the performance, Dr Satish Wagh, Executive Chairman and Whole Time Director of Supriya Lifescience, said that the company’s strong Q4FY26 and full-year performance reflects healthy demand across key therapeutic segments, strong traction in regulated markets, and continued operational focus. He added that improved capacity utilisation, expansion into global markets, and contributions from newly launched products supported growth during the year.
He further stated that the company remains focused on strengthening manufacturing capabilities, backward integration, innovation, and finished dosage expansion to drive sustainable long-term growth.
Share Price and Technical Indicators
Supriya Lifescience shares have delivered strong long-term returns, rallying nearly 215% over the last three years. The company currently has a market capitalisation of around Rs 6,496 crore.
Also read: Up to 531% returns: 23 small & midcap multibaggers you might have missed in 2026
From a technical perspective, the stock continues to remain in a strong bullish trend, trading above all 8 out of 8 key simple moving averages (SMAs). However, the 14-day Relative Strength Index (RSI) stands at 75.9, indicating overbought conditions. An RSI above 70 generally suggests the possibility of near-term profit booking or a temporary pullback.
